At The Conversation, Council researcher Karen Austrian discussed how the Adolescent Girls Initiative-Kenya (AGI-K) program is reaching vulnerable girls in urban and rural communities who are at risk of dropping out of school, sexual violence and early sexual initiation, early and unintended pregnancy, and early marriage.
_211_141.jpg)
September 24, 2018 – New research by the Population Council and partners shows that it may be possible to formulate a discreet, convenient, and woman-controlled multi-purpose technology to prevent HIV and other sexually transmitted infections (STIs) with limited risk of cross-resistance to antiretrovirals (ARV). This research published today in Nature Communications tests the non-antiretroviral agents, griffithsin (GRFT) and carrageenan (CG), in a fast-dissolving vaginal insert in rhesus macaques and mice.
In a video interview, Judith Bruce explains that financial concerns can take much of the sentimentality and romance out of marriage.
The Population Council is co-hosting a seminar series exploring the links between people and their environments in our fast-changing global landscape. Convened in partnership with the Center for International Earth Science Information Network (CIESIN) at Columbia University, the CUNY Institute for Demographic Research (CIDR), and the UN Population Division, this seminar series will feature key experts from the fields of demography, climate and public health sharing insights on their interdisciplinary work to measure and solve climate related challenges.
The Population Council, a global nonprofit research organization, announced it has received U.S. Food and Drug Administration (FDA) approval for Annovera™ (segesterone acetate and ethinyl estradiol vaginal system), the first and only contraceptive that provides an entire year of protection against unintended pregnancy while fully under a woman’s control. The approval marks an important step toward expanding contraceptive options for women.
In a timely op-ed at Project Syndicate, Thoai Ngo, Director of the GIRL Center, argues that researchers, programmers, and donors should embrace open data as a critical tool to promote sound investments and ensure efforts to improve girls’ lives are informed by evidence, not intuition.
Today the Population Council announced a new license agreement with TherapeuticsMD to make available the Council's investigational segesterone acetate/ ethinyl estradiol one-year vaginal system for contraception, to women in the United States. The agreement marks an important step toward expanding contraceptive options for women.
Without investing in women’s sexual and reproductive health and rights, the world cannot drive societal progress to achieve the Sustainable Development goals, argues Zeba Sathar, Pakistan Country Director for the Population Council and Marleen Temmerman, Director of the Center of Excellence in Women and Child Health and Chair of the Department of Obstetrics and Gynaecology at the Aga Khan University.
Next week more than 15,000 global leaders, policy makers, researchers, and advocates from 160 countries will gather in Amsterdam for #AIDS2018 to share the latest in HIV prevention, treatment and cure research, and insights on the global agenda.
NEW YORK, NY (June 21, 2018) – A new Phase I study of the Population Council’s multipurpose prevention technology (MPT) gel PC-1005, launching this week, will examine the safety of the gel when used rectally by both men and women. If proven effective, PC-1005 gel would be the first product to prevent three incurable sexually transmitted infections (STIs)—HIV, herpes simplex virus (HSV), and human papillomavirus (HPV)—when used either vaginally or rectally.
